Feature | June 11, 2014

GE Healthcare Unveils Upgradeable PET/CT System

June 11, 2014 — GE Healthcare introduced its Discovery IQ PET/CT (positron emission tomography/computed tomography) system at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. The system enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA) and not available for sale in the United States.

Discovery IQ

Physicians not only want the ability to detect smaller lesions, but also the ability to determine earlier whether the patient is responding to current treatment. With high sensitivity up to 22 cps/kBq, the largest axial field-of-view (up to 26 cm) and quantitative SUV measurements, Discovery IQ provides an essential tool to delivering personalized patient care. It enables physicians to see smaller lesions, scan faster with lower dose and improved image quality, read more efficiently, and reach more patients.

“By 2020, it’s estimated that 50 percent of people will develop cancer at some point in their lives, and we also know that currently approximately 70 percent of cancer patients do not respond to their initial chemotherapy treatment,” said Steve Gray, president and CEO of GE Healthcare MICT. “I’m excited to introduce the Discovery IQ to help physicians with their primary mission of delivering the best possible patient outcomes.  And, we’ve focused on designing the system to make it as accessible as possible to more people in more places, to ensure high-performance PET/CT clinical care is available to whomever needs it.”

Some key features include:

  • GE Healthcare’s Q.Clear PET reconstruction technology, providing up to two times improvement in both image quality and quantitation accuracy;
  • A fully scalable system, allowing for the ability to upgrade as department needs change;
  • Availability for the mobile market, enabling the latest technology across both fixed and mobile environments;
  • New platform design and the new LightBurst detector technology, allowing for whole organ imaging via fast scans at low dose to help maximize patient comfort and safety; and
  • Fast electronics and a dual acquisition channel that enables high quantitative accuracy for all clinically relevant tracers.


Q.Clear

The Q.Clear technology is a critical component of Discovery IQ. It delivers, for the first time, no trade-off between image quality and quantitative SUV measurements. By providing two times improvement in both quantitative accuracy and image quality in PET/CT imaging, this innovative new tool provides benefits to physicians across the cancer care continuum from diagnosis, staging and treatment planning, to treatment assessment.

Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. The new Q.Clear technology shows the advantage of full convergence PET imaging with no compromise between quantitation and image quality. 

CortexID Suite

CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans, enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3-D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism and in PET brain amyloid load between a subject’s images and a normal database, which may be the result of brain neurodegeneration.

For more information: www.gehealthcare.com

Related Content

SNMMI, appropriate use criteria, AUC, PAMA, qualified provider-led entity, PLE
News | Clinical Decision Support| June 27, 2016
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-led entity (PLE)...
Philips, SNMMI 2016, Vereos digital PET/CT, time-of-flight, IntelliSpace 8.0, nuclear imaging
News | Nuclear Imaging| June 14, 2016
Philips announced it would be showcasing a variety of nuclear imaging solutions at the Society of Nuclear Medicine and...
Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration
Technology | Nuclear Imaging| June 09, 2016
At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens Healthineers will...
nuclear medicine, global market, radiopharmaceuticals, MEDraysintell, SNMMI 2016
News | Nuclear Imaging| June 08, 2016
MEDraysintell estimates that the global market for nuclear medicine (radiopharmaceuticals) reached $4.3 billion in 2015...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biography scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging| June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
Medic Vision, SafeCT-29, NEMA XR-29, Smart Dose, computed tomography
Technology | Computed Tomography (CT)| May 31, 2016
Medic Vision Imaging Solutions Ltd. announced the U.S. Food and Drug Administration (FDA) clearance of SafeCT-29 to...
Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
News | Radiopharmaceuticals and Tracers| May 13, 2016
NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research...
GE Healthcare, general purpose digital SPECT/CT, Discovery NM/CT 670 CZT, Barnes-Jewish Hospital, first U.S. install
News | SPECT-CT| May 05, 2016
Doctors and researchers at Barnes-Jewish Hospital and Washington University in St. Louis may be able to better diagnose...
Overlay Init